loading









  • We are a biopharma company
    focused on the development of
    innovative botanical drugs
    in oncology supportive care
    and dermatology
We develop products where options are limited



Indications / Claims
Preclinical
Phase 1
Phase 2
Phase 3
 
Market
Brandnames
Partners
Hair Loss
CG 210 / qilib
 
Advanced Hair Loss
CG 428
Pediatric Alopecia Areata (AA)
 Charité 1
Chemotherapy-Induced Alopecia (CIA)
CHUV 2
Permanent CIA (PCIA)
Cancer Related Fatigue (CRF)


(1) “Clinical Research Center for Hair and Skin Science” / the “Charité-Universitätsmedizin Berlin” cooperates with Legacy in conducting a study with name “RAAINBOW”.
(2) Centre Hospitalier Universitaire Vaudois (CHUV), Medical Oncology service of the Oncology Department of UNIL-CHUV
Our work was presented at major scientific congresses.


Year
Country
Conference
Field
2017
Singapore ESMO Asia 2017 Oncology supportive care
Japan 10th World Congress for Hair Research Dermatology
US Multinational Association of Supportive Care in Cancer Oncology supportive care
Thailand 42nd Annual Scientific Meeting of the Dermatological Society of Thailand Dermatology
2016
US American Academy of Dermatology Dermatology
US Alopecia Areata Research Summit NAAF Alopecia Areata
Greece EADV Dermatology
Australia Multinational Association of Supportive Care in Cancer Oncology supportive care
Thailand 41st Annual Scientific Meeting of the Dermatological Society of Thailand Dermatology
US American Association for Cancer Research Oncology supportive care
2015
Denmark EADV Dermatology
US Multinational Association of Supportive Care in Cancer Oncology supportive care
US American Association for Cancer Research Oncology supportive care
US National Consortium of Breast Centers Oncology supportive care
US Young Survival Coalition Oncology supportive care
US Oncology Nursing Society Oncology supportive care
2014
Singapore Singapore International Conference on Skin Research Dermatology
US American Academy of Dermatology Dermatology
Serbia EADV Dermatology
US San Antonio Breast Cancer Symposium Oncology supportive care
US Young Adult Cancer Alliance Oncology supportive care
Korea World Congress for Hair Research Hair Science
US Young Adult Cancer Alliance Oncology supportive care
US Society of Integrative Oncology Oncology supportive care
US World Congress on Breast Cancer Oncology supportive care
US American Association for Cancer Research Oncology supportive care
US Multinational Association of Supportive Care in Cancer Oncology supportive care
2013
Turkey EADV Dermatology
Scotland World Congress for Hair Research Hair Science
US American Association for Cancer Research Oncology supportive care
US Multinational Association of Supportive Care in Cancer Oncology supportive care
2012
Bahamas International Society for Hair Restoration Surgery Hair Science
Japan Japan Society of Clinical Hair Restoration Hair Science



Publications

Cucé LC et al., Cellium® GC: evaluation of a new natural active ingredient in 210 mg/ml topical solution, through scalp biopsy. Surg Cosmet Dermatol 2011; 3(2): 123-128
Takeda A et al., CG210 Enables Finasteride 1mg Users to Further Improve Hair Pattern: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hair Ther Transplant 2013; 3: 107

Management





team altea

Saad Harti
Founder and CEO

Saad has started in the financial field, at Arthur Andersen. He later co-founded Altacare, a healthcare business development firm active in more than 50 markets. Saad has pioneered contraceptive-access programs in developing countries.
Saad is the founder of Legacy and manages the company.



team altea

Geert Cauwenbergh, Ph.D.
Partner

Geert founded Barrier Therapeutics, a dermatology company in 2001. After bringing Barrier to success it was acquired by Stiefel in 2008. Prior to founding Barrier, Geert was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a board member of several dermatology companies. He has authored more than 100 publications.
Geert is a shareholder of Legacy and acts as strategic and scientific advisor.



team altea

JiaWei Liu, Ph.D.
VP R&D

Active in international academic and pharmaceutical industry, JiaWei successfully developed quality research projects in Chinese Academy of Sciences, Geneva and Lausanne University Hospitals. He was previously responsible for new drug search & evaluation Asia at the Swiss drug development company Debiopharm Group.
He also engaged in teaching activities at Harvard Medical School in 2013 and 2014. As Legacy Healthcare’s Vice President, he is in charge of the company’s R&D activities.



team altea

Michel Chretienne, Pharm D.
VP Quality

Michel has served as Pharmaceutical Director and Pharmacist in charge at Hoechst Marion Roussel (Aventis) until 1999. Michel is involved in a number of professional and scientific societies such as the French Association of Regulatory Affairs, Member of the Ethic Committee and Mediation of the French pharmaceutical industry (CEMIP) etc.
Michel is responsible of the quality and manufacturing affairs of Legacy.



team altea

Nadine Vincent, Pharm D.
Head of Regulatory

Nadine has a pharmaceutical education and management training (INSEAD). She spent 30 years at Hoechst Marion Roussel, first in Research & Development and then as International Strategic Regulatory manager in charge of registering the key anti-infective products. She then joined HRA Pharma, where she stayed for over 15 years as Regulatory Affairs Director. Nadine has managed the registration of multiple products with EMA, FDA, PDMA, etc. Nadine is in charge of Regulatory Affairs.



team altea

Marcos Val
Chief Financial Officer

Marcos has spent over 15 years in corporate Healthcare and FMCG international finance leadership roles. In particular with Medtronic, as part of his Europe & Canada director role he supported the Biopharma Organization set up : pioneers in the launch of multi-million spine and neurocience drug products. Later in his career, he has successfully raised funds and coached healthcare startups while also carrying due diligence work for investor groups.



team altea

Bruce Patsner, M.D., J.D.
North American Operations Director

Active in women’s cancer care and medical research in the United States and Asia for 30 years, Bruce later trained in health law and Cal Berkeley and Harvard Law Schools; was a Senior Medical Officer at the United States FDA; and later worked in Pharmacovigilance at Genzyme/Sanofi in Cambridge, Massachusetts. He has extensive experience in clinical trial design and more than 100 publications in Oncology and food and drug law. Bruce is the Director of North American Operations for Legacy.



team altea

Tadafumi Shiiba
General Manager Japan

Tadafumi Shiiba, 44, General Manager for Legacy Healthcare KK (Japan), has accumulated experience working for medical corporations for more than 15 years. He served as sales representative at KOLs level in the fields of orthopedic surgery and gastroenterology at Smith & Nephew and Suzuken in Japan. He then joined Legacy Healthcare in 2012 first as a sales manager. He initially deployed CG 210 in several physician dispensing clinics and later on CG 428 in more than 60 oncology clinics. Thanks to his skills, Tadafumi managed to raise interest and convince two KOLs to conduct important self-funded clinical trials on the product in two hospitals in Japan.


Advisors and Investigators

























Institutions & foundations we are proud to work with
The National Alopecia Areata Foundation (NAAF), San Rafael, US
http://www.naaf.org
team altea


Contact

map





Switzerland office
Rte de la Corniche 3B
1066 Epalinges (Lausanne)
Tel: +41 21 552 21 70

Email: contact@legacyhealthcare.ch

France office
27 Avenue de l'Opéra
75001 Paris - France
Tel: +33 1 70 38 54 83

Email: contact.fr@legacyhealthcare.ch

Japan office
TOC Daiichi Bldg. 6F
1-8-3 Shibuya, Shibuya-ku, Tokyo 150-0002
Tel: +81 3-6805-0651

Email: contact.jp@legacyhealthcare.ch

Copyright © 2017 Legacy Healthcare / All rights reserved.